Prior research has indicated that the concomitant use of risperidone with VPA may influence VPA metabolism through its binding to albumin, potentially resulting in elevated blood ammonia levels and an increased risk of HE (Rodrigues-Silva et al., 2013). This evidence concerns the gene ALB and hereditary elliptocytosis.